William Blair Has Positive Estimate for DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Analysts at William Blair raised their FY2024 earnings per share (EPS) estimates for Dynavax Technologies in a report issued on Monday, January 13th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of $0.16 per share for the year, up from their previous estimate of $0.15. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share.

Several other research analysts have also weighed in on the company. HC Wainwright upped their price target on Dynavax Technologies from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday. StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday.

Dynavax Technologies Price Performance

NASDAQ:DVAX opened at $12.48 on Wednesday. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of 96.01 and a beta of 1.34. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $14.41. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average price is $12.77 and its 200 day moving average price is $11.66.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds have recently modified their holdings of DVAX. GAMMA Investing LLC increased its stake in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 1,457 shares during the period. Sanctuary Advisors LLC increased its position in shares of Dynavax Technologies by 9.1% in the third quarter. Sanctuary Advisors LLC now owns 17,727 shares of the biopharmaceutical company’s stock valued at $197,000 after acquiring an additional 1,484 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 1,679 shares during the last quarter. US Bancorp DE increased its position in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of Dynavax Technologies by 1.2% during the third quarter. Parkman Healthcare Partners LLC now owns 219,451 shares of the biopharmaceutical company’s stock worth $2,445,000 after acquiring an additional 2,629 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.